Anat Cohen-Dayag: So, Henry, you’ll start will breast. And then, Eran will take the biomarker and HCC expression.
Henry Adewoye: Yes. Thank you for the question. With regards to breast cancer data, all I can see at this point is that the patient population that we’ve enrolled, a patient population that’s heterogeneous with respect to whether they’re ER/PR positive or ER/PR negative or HER2 negative, this is a patient population that have exhausted all available standard of care therapies, including therapies that are approved, such as tucatinib [ph]. Now, the important thing that we’re looking for in this patient population is to see a signal of anti-tumor activity and that will confirm to us that there is activity with the combination that we are pursuing with COM701 plus nivolumab. So that’s what would be of interest to us, especially in these hard to treat patient populations that have possibly received several lines of therapy.
Eran Ophir: Yes, then for the questions about the biomarkers. So, yes, we anticipate that the same biomarkers that would inform or that we learn from in the study of using the BMS TIGIT should be relevant also for the other studies that we are doing, both BMS TIGIT and our COM902 are Fc non-active. And in general that was a study of blocking triple blockade of TIGIT, PD-1 and PVRIG. So biologically it should be very similar to the study that we are currently conducting. And if you will identify some new translational or potential predictive biomarkers in that study, we definitely think it could be and should be relevant also to the follow-up study that we are currently doing. Now about the HCC. So we identified ovarian endometrial as one of the top indication with dominance of the pathway and that’s why we went to these indications, also breast.
But HCC is definitely one of the top expressers of the pathway. We couldn’t start with all of them. And PVRL2 is quite broadly expressed in many indications. So, HCC is definitely an indication in which the pathway is dominant and it’s the target indication that we definitely see a potential in.
Anat Cohen-Dayag: And just in terms of whether we’re going to test the indication to your specific questions, I think that it is being shown out that the PVRIG blockade potential, the COM701 therapeutic potential, is much broader than the 2 indications that we’re focusing right now. We’ve took to focus on these 2 indications where we have data and where we believe that additional data that we will expand with these studies may allow us to better design the path forward. But I want to stress that again and again, the therapeutic potential of COM701 is much beyond these 2 indications and it includes endometrial cancer, and non-small cell lung cancer, and HCC. And as we said, we’ll present data in breast towards the end of the year. That’s very encouraging to us.
Henry Adewoye: I think one of the other questions you asked was, if there was any substantive difference between the triplets that we’re currently exploring in the ovarian cancer space, which is the triplet I’m referring to now is COM902, plus COM701, plus pembrolizumab versus the earlier triplet, which is the triplet with the BMS TIGIT antibody BMS-986207 and nivolumab. As a reminder, we did have a press release, when we enrolled the first patient into the current triplet of COM902, COM701 and pembrolizumab. And as part of what we said was that we did not – this was one of the investigators on that study. The initial observation is that this combination, which is the pembrolizumab containing triplet of COM902, COM701 and pembro, is very well tolerated as observed, at least in the patient population with microsatellite stable colorectal cancer in the initial study that we enrolled.
So there are no differences observed so far. And this is earlier on as we enrolled colorectal patients, microsatellite stable colorectal cancer patients. We do not expect there to be any substantive differences in terms of safety and tolerability. I hope that answers your question.
